Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160436 | 0.92 | HDAC3 (0.51) | SMN1; SMN2HDAC3HDAC1HDAC2NAAA | |
| SCHEMBL162958 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2HDAC3HDAC1HDAC2NAAA | |
| SCHEMBL163498 | 0.86 | HDAC3 (0.43) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL163094 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2HDAC3HDAC1HDAC2NAAA | |
| SCHEMBL161737 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2HDAC3HDAC1HDAC2NAAA | |
| SCHEMBL6358652 | 0.80 | HDAC3 (0.74) | SMN1; SMN2HDAC3HDAC1HDAC2NAAA | |
| SCHEMBL162512 | 0.80 | KMT2A (0.54) | SMN1; SMN2HTTRAB9AHPGDOPRM1 | |
| SCHEMBL163477 | 0.79 | PLK1 (0.44) | SMN1; SMN2HDAC3HDAC1HDAC2TSHR | |
| SCHEMBL162959 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2HDAC3HDAC1HDAC2NAAA | |
| SCHEMBL15204760 | 0.76 | ALDH1A1 (0.51) | SMN1; SMN2HTTRAB9AHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | SMN1; SMN2 1/4885HDAC3 1776/4885HDAC1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.